Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Antiretroviral medications during pregnancy for therapy or prophylaxis.

Stek AM.

Curr HIV/AIDS Rep. 2009 May;6(2):68-76. Review.

PMID:
19358777
2.

Lopinavir exposure with an increased dose during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS; PACTG 1026s Study Team.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):485-91. doi: 10.1097/QAI.0b013e318186edd0.

3.

Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.

Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, Burchett SK, Smith ME, Sheeran EC, Shearer WT, Febo I, Mirochnick M.

HIV Med. 2008 Nov;9(10):875-82. doi: 10.1111/j.1468-1293.2008.00640.x. Epub 2008 Sep 14.

4.

Adherence to antiretrovirals among US women during and after pregnancy.

Bardeguez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, Stek A, Buschur S, Cotter A, Bettica L, Read JS; PACTG 1025 Protocol Team.

J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):408-17. doi: 10.1097/QAI.0b013e31817bbe80.

5.

Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women.

Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, Higgins A, Zorrilla C, Landesman S, Serchuck L, Larussa P.

AIDS Care. 2008 Sep;20(8):958-68. doi: 10.1080/09540120701767208.

PMID:
18608073
6.

Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.

European Collaborative Study, Patel D, Cortina-Borja M, Thorne C, Newell ML.

Clin Infect Dis. 2007 Jun 15;44(12):1647-56. Epub 2007 May 2.

7.

Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.

Cressey TR, Lallemant M.

Infect Genet Evol. 2007 Mar;7(2):333-42. Epub 2006 Oct 11. Review.

PMID:
17045554
8.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
9.

Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview.

Bartlett JA, Buda JJ, von Scheele B, Mauskopf JA, Davis EA, Elston R, King MS, Lanier ER.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):323-31. Review. Erratum in: J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):381.

PMID:
16540933
10.
11.

The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women.

Anastos K, Schneider MF, Gange SJ, Minkoff H, Greenblatt RM, Feldman J, Levine A, Delapenha R, Cohen M; Women's Interagency HIV Study Collaborative Group.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):537-44.

PMID:
16044004
12.

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.

European Collaborative Study.

Clin Infect Dis. 2005 Feb 1;40(3):458-65. Epub 2005 Jan 7.

13.

Risk factors for in utero and intrapartum transmission of HIV.

Magder LS, Mofenson L, Paul ME, Zorrilla CD, Blattner WA, Tuomala RE, LaRussa P, Landesman S, Rich KC.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):87-95.

PMID:
15608531
14.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team.

N Engl J Med. 2002 Jun 27;346(26):2039-46.

15.

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, Blattner W; Women and Infants' Transmission Study Group.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94.

PMID:
11981365
16.

From the Centers for Disease Control and Prevention. Progress toward elimination of perinatal HIV infection--Michigan, 1993-2000.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2002 Feb 8;51(5):93-7.

17.

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF.

N Engl J Med. 1999 Aug 5;341(6):394-402.

18.

Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, Moye J Jr, Reichelderfer P, Harris DR, Fowler MG, Mathieson BJ, Nemo GJ.

N Engl J Med. 1999 Aug 5;341(6):385-93.

19.

The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group.

Thea DM, Steketee RW, Pliner V, Bornschlegel K, Brown T, Orloff S, Matheson PB, Abrams EJ, Bamji M, Lambert G, Schoenbaum EA, Thomas PA, Heagarty M, Kalish ML.

AIDS. 1997 Mar 15;11(4):437-44.

PMID:
9084790
20.

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al.

N Engl J Med. 1994 Nov 3;331(18):1173-80.

Items per page

Supplemental Content

Write to the Help Desk